Terns Pharmaceuticals Inc (TERN) USD0.0001
Terns Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The Company’s NASH pipeline includes multiple single-agent and combination therapy candidates that provide opportunities to address the multifaceted nature of NASH and provide clinical benefits for patients. The Company’s TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) that has demonstrated a profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-101 is in a Phase 2a clinical trial. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. The TERN-201 is in Phase 1b clinical trial. Its TERN-501 is in Phase 1a clinical trial.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.